title: Changes in chemiluminescence of whole blood of COPD patients treated with Hypoxen and effects of C₆₀ fullerenes on blood chemiluminescence.
abstract: BACKGROUND
  Chronic obstructive pulmonary disease (COPD) is an inflammatory disease associated with reactive oxygen species (ROS) production. The aim of this study was to evaluate the effect of Hypoxen treatment and the effect of HyFnC₆₀ on ROS production in patients' blood.
  
  
  METHODS
  ROS production in blood was estimated using chemiluminescence (CL) measurement with CL-amplifiers: luminol (LM), LM + zymosan (ZM) or lucigenin (LC) in the presence or absence of hydrated fullerenes (HyFnC₆₀) added to blood in low concentrations.
  
  
  RESULTS
  In all the patients with COPD in remission phase with Hypoxen prescription, the LM-dependent CL (LM-CL) with ZM and LC-enhanced CL (LC-CL) decreased after the treatment. Parameters of CL and effects of HyFnC₆₀ upon them depended on blood state. Addition of HyFnC₆₀ to blood decreased data scattering and helped to improve discrimination between different groups of patients. Using the discriminator analysis, we found the most important time-points in the kinetic curves of CL for classification of patients into groups (eg, COPD patients before and after treatment with Hypoxen; patients' blood with different sensitivity to HyFnC₆₀ concentration).
  
  
  CONCLUSIONS
  Monitoring of CL of non-diluted whole blood in COPD patients can be used for the estimation of the Hypoxen efficiency in complex therapy. Addition of HyFnC₆₀ to blood increases sensitivity of the method.
authors.affiliation: Faculty of Biology, M.V.Lomonosov Moscow State University, Moscow, Russia. kirniknov@yandex.ru
authors.forename: Kirill N
authors.initials: KN
authors.lastname: Novikov
authors.forename: Nadezhda G
authors.initials: NG
authors.lastname: Berdnikova
authors.forename: Alexey K
authors.initials: AK
authors.lastname: Novikov
authors.forename: Oksana Y
authors.initials: OY
authors.lastname: Lyusina
authors.forename: Olga G
authors.initials: OG
authors.lastname: Muhitova
authors.forename: Olga I
authors.initials: OI
authors.lastname: Yablonskaya
authors.forename: Ha Do
authors.initials: HD
authors.lastname: Minh
authors.forename: Vladimir L
authors.initials: VL
authors.lastname: Voeikov
mesh_terms: D000368:Aged; D005260:Female; D037741:Fullerenes / Q000627:therapeutic use*; D006801:Humans; D049449:Luminescence; D008297:Male; D008875:Middle Aged; D010647:Phenyl Ethers / Q000627:therapeutic use*; D011446:Prospective Studies; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood* / Q000188:drug therapy*; D017382:Reactive Oxygen Species / Q000097:blood
chemical_list: D037741:Fullerenes; D010647:Phenyl Ethers; D017382:Reactive Oxygen Species; C085806:olifen; C069837:fullerene C60